Objectives: To investigate whether the serum fibroblast growth factor (FGF) 21 levels can be used to predict the future development of major adverse cardiovascular events (MACEs).

Methods: 253 patients at baseline received subsequent follow-up, 234 of whom finished the data collection. Independent predictors of MACEs were identified using Cox proportional hazards regression analysis. The prognostic value of FGF-21 levels for MACEs was evaluated by Kaplan-Meier survival analysis.

Results: Of 229 patients finally enrolled in the analysis, 27 of 60 without coronary artery disease (CAD) at baseline experienced a MACE, and 132 of 169 patients with CAD at baseline experienced a MACE. Among patients with CAD at baseline, serum FGF-21 levels were significantly higher in patients with MACEs (P<0.05) than in patients without MACEs. Kaplan-Meier survival analysis showed a significantly lower event-free survival (P=0.001) among patients with a higher serum FGF-21 level than in those with a lower serum FGF-21 level. Further Cox proportional hazards regression analysis, including the traditional risk factors for cardiovascular disease, showed that serum FGF-21 was one of the independent predictors of the occurrence of MACEs.

Conclusions: In patients with CAD at baseline, an elevated serum FGF-21 level was associated with the development of a MACE in the future.

Disclosure

Y. Bao: None. Y. Shen: None. X. Zhang: None. Y. Xu: None. Q. Xiong: None. Z. Lu: None. X. Ma: None.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.